Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLIA and Quizartinib for AML and High-Risk MDS
NCT04047641Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2019
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of quizartinib in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), Acute Biphenotypic Leukemia (BAL), sponsored by University of Texas MD Anderson Cancer Center. Started Oct 2019; status: recruiting.
02
Drugs
quizartinib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)Acute Biphenotypic Leukemia (BAL)
Beyond the preview
Go deeper on NCT04047641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04047641.